Acta Dermato-Venereologica (Oct 2021)

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

  • Antonio Costanzo,
  • Filomena Russo,
  • Marco Galluzzo,
  • Luca Stingeni,
  • Roberta Scuderi,
  • Leonardo Zichichi,
  • Manuela Papini,
  • Luisa Di Costanzo,
  • Andrea Conti,
  • Martina Burlando,
  • Andrea Chiricozzi,
  • Francesca Maria Gaiani,
  • Cristina Mugheddu,
  • Maria Letizia Musumeci,
  • Paolo Gisondi,
  • Stefano Piaserico,
  • Paolo Dapavo,
  • Marina Venturini,
  • Gianluca Pagnanelli,
  • Paolo Amerio,
  • Concetta Potenza,
  • Ketty Peris,
  • Franca Cantoresi,
  • Sara Trevisini,
  • Francesco Loconsole,
  • Annamaria Offidani,
  • Santo Raffaele Mercuri,
  • Viviana Lora,
  • Francesca Prignano,
  • Marta Bartezaghi,
  • Giovanni Oliva,
  • Elisabetta Aloisi,
  • Roberto Orsenigo

DOI
https://doi.org/10.2340/00015555-3816
Journal volume & issue
Vol. 101, no. 10

Abstract

Read online

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Keywords